News zum Sektor Gesundheit aus Asien

 

3SBIO (01530.HK) announced that it repurchased 1 million shares on Oct 12 at prices ranging from HKD14.7 to HKD14.9 per share, involving approximately HKD14.8 million.Since the repurchase mandate resolution was passed, the group has cumulatively repurchased 22.963 million shares, accounting for 0.91% of its issued shares. (su)~A......

HKEX (00388.HK) announced that it will add 12 single stock option classes on November 9, covering KINGBOARD HLDG (00148.HK), ASMPT (00522.HK), KB LAMINATES (01888.HK), CHINAGOLDINTL (02099.HK), CSOP HS TECH (03033.HK), HANSOH PHARMA (03692.HK), GIGADEVICE (03986.HK), BIREN TECH (06082.HK), CIG (06166.HK), MONTAGE TECH (06809.HK)......

LEADS BIOLABS-B (09887.HK) announced that its core product Vilastobart (Opretisumab, a PD-L1/4-1BB bispecific antibody) has received Fast Track designation from the US FDA for the first-line treatment of advanced biliary tract cancer (BTC). This marks the second FDA Fast Track designation obtained by the product following extrap......

YIDU TECH (02158.HK) announced that it entered into a secured loan product provided by Goldman Sachs on May 26 last year, involving a loan amount of USD65 million. The transaction constituted a discloseable transaction and also constituted an advance to an entity, but the company failed to publish an announcement for the transac......

EDDING GENOR (06998.HK) announced that the Investigational New Drug (IND) application for a Phase II clinical trial of its highly differentiated and innovative PD-1/CTLA-4/VEGF trispecific antibody GB268 in combination with chemotherapy as a first-line treatment for unresectable locally advanced or metastatic colorectal adenocar......

Second FDA Fast Track Designation for Opamtistomig Underscores Its Potential in Immunologically Cold Tumors Second FDA Fast Track Designation for Opamtistomig Underscores Its Potential in Immunologically Cold Tumors...

3SBIO (01530.HK) announced that it repurchased 2.5 million shares last Friday (9th) at prices ranging from HKD14.98 to HKD15.18 per share, involving approximately HKD37.588 million.AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automatically translated by AI, the Chinese version should be considered the authori......

ICP-B161 delivers an extended half‑life, which allows for less frequent dosing and supports subcutaneous administration....

HONG KONG, Oct. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, as monotherapy in......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

CytoMed Therapeutics Limited (the “Company”) (NASDAQ: GDTC), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies, today announced that on October 6, 2026, the Company received a notice from the staff of the Nasdaq Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that for the last 30 consecutive business days, the closing bid price of the Company's ordinary shares (the “Ordinary Shares”) was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Nasdaq notification letter has no current effect on the listing or trading of the Company's Ordinary Shares on Nasdaq....

Find insight on GSK, Terumo and more in the latest Market Talks covering the health care sector....

Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the positive 52-week clinical results from the Phase 3 ASC40-304 open-label extension of denifanstat in patients with moderate to severe acne vulgaris, conducted by license partner Ascletis BioScience Co. Ltd. (Ascletis) in China, along with mechanistic data, will be presented at the 2026 Fall Clinical Dermatology Conference taking place October 8-11, in Las Vegas, Nevada. Denifanstat is a once-daily oral small molecule fatty acid synthase (FASN) inhibitor being developed by Ascletis as ASC40 in China where it holds an exclusive license to denifanstat, and by Sagimet in the rest of the world....

SIMCERE PHARMA (02096.HK) announced that it repurchased 1.598 million shares on October 9 at prices ranging from HKD10.66 to HKD11.003 per share, involving approximately HKD17.3699 million.AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automatically translated by AI, the Chinese version should be considered the......

How quality, supply resilience, manufacturing excellence and innovation are supporting the next generation of biologics. MILAN, Oct. 9, 2026 /PRNewswire/ -- Europe's biologics sector is expanding as ageing populations and the rising burden of chronic, autoimmune and rare diseases increase......

SHANGHAI and HONG KONG, Oct. 8, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for......

Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, PhD, former Research & Early Translational Lead, Cancer Vaccines at Moderna, join Everest Medicines Appointments support continued advancement of Everest's mRNA......

3SBIO (01530.HK) announced that it repurchased 1.7 million shares yesterday (8 Oct), at a price ranging from HKD15.4 to HKD15.75 per share, involving approximately HKD26.5 million.AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automatically translated by AI, the Chinese version should be considered the authorit......

SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid Eye Disease(TED) SAN FRANCISCO and SUZHOU, China, Oct. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")......

Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...